FierceBiotechOriginal article
{"a":[{"_":"Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi","$":{"href":"/biotech/corbus-posts-phase-1-obesity-data-area-where-novo-and-sanofi-stumbled","hreflang":"en"}}]}
Phase 1positivePositive
AI Analysis
Summary
Corbus Pharmaceuticals reported positive phase 1b obesity trial data for its CB1 inverse agonist showing a potentially improved safety profile compared to prior competing approaches by Novo Nordisk and Sanofi, with plans to advance to phase 2.
Clinical Trial Data
Phase
1b
Outcome Details
Phase 1b data showed evidence of reduced neuropsychiatric side effects compared to competing mechanisms
Importance:6/10
Sentiment:
0.70
obesityCB1 inverse agonistphase 1bsafety profileneuropsychiatric side effects
Related Companies
Read the original article
Published by FierceBiotech on September 14, 2026 10:07 AM
